To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment.

METHODS:

In this prospective observational study, 53 patients received sleeve gastrectomy (n = 10), semaglutide therapy (n = 23), or the DEAR programme (n = 20) after multidisciplinary assessment and shared decision-making. Anthropometric and metabolic measures and tumour response were assessed over two years.

RESULTS:

At 1 year, all groups lost weight; the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group (difference = 4.04 kg/m², p < 0.05) and the DEAR group (difference = 2.12 kg/m², p < 0.05). By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (p = 0.037). The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%).

CONCLUSION:

Sleeve gastrectomy produced rapid short-term weight loss, whereas the DEAR programme showed better medium-term weight maintenance, metabolic stability, and tumour response. Integrated lifestyle support may be a useful medium-term strategy for patients seeking fertility preservation.

2026-11-01·SCHIZOPHRENIA RESEARCH

Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis

Article

作者: Monteiro, Amanda ; de Vasconcelos, Anna Victoria ; Marçal, Jordana Belgamasco Cavalcanti ; Graciolli, Letícia Hanna Moura da Silva Gattas ; Sobral, Milene Vitória Sampaio ; Maciel, Rafaela Correia ; Menechini, Rodrigo Bettanim ; Amador, Wellgner Fernandes Oliveira ; Acuia, Thaísa Aparecida de Souza

BACKGROUND:

Individuals with schizophrenia have markedly increased cardiometabolic morbidity, largely attributable to antipsychotic-induced weight gain, insulin resistance, and dyslipidemia, particularly with clozapine- and olanzapine-based regimens. This systematic review and meta-analysis evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in antipsychotic-treated patients with schizophrenia.

METHODS:

PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to September 16, 2025 for randomized clinical trials comparing GLP-1RAs with placebo or standard care. The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was prospectively registered in PROSPERO (CRD420251177261). Random-effects models were used to pool mean differences (MDs) and risk ratios (RRs).

RESULTS:

Eight randomized clinical trials including 523 participants were analyzed. GLP-1RAs significantly reduced body weight (MD -6.47; 95% CI, -9.61 to -3.32), body mass index (MD -2.83; 95% CI, -3.81 to -1.86), waist circumference (MD -5.35; 95% CI, -6.60 to -4.09), and glycated hemoglobin levels (MD -0.32; 95% CI, -0.39 to -0.26) compared with placebo or standard care. Exploratory subgroup analyses suggested marked differences across individual agents: exenatide showed a smaller and non-significant reduction in body weight, liraglutide showed a significant moderate reduction, and semaglutide showed the largest reduction. No significant effects were observed for fasting insulin, lipid parameters, or blood pressure. Gastrointestinal adverse events were more frequent with GLP-1RAs.

CONCLUSIONS:

In this systematic review and meta-analysis, GLP-1RAs were associated with clinically meaningful improvements in anthropometric and glycemic outcomes in antipsychotic-treated patients with schizophrenia, with acceptable tolerability primarily characterized by gastrointestinal adverse events.

2026-08-18·POSTGRADUATE MEDICINE

Evidence-informed guidance for the clinical use of oral semaglutide in obesity management

Review

作者: Knight, Michael G. ; Aroda, Vanita R. ; Wharton, Sean ; Rubino, Domenica

Oral semaglutide, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for the treatment of type 2 diabetes, is now approved for obesity management and cardiovascular risk reduction in adults, demonstrating weight loss comparable to that of subcutaneous GLP-1 therapies, alongside improvements in cardiometabolic risk factors. The availability of oral semaglutide for the treatment of obesity provides healthcare professionals with additional opportunities to individualize therapy based on patient preferences, lifestyle, and clinical circumstances. However, the oral semaglutide formulation requires specific administration conditions to optimize absorption and effectiveness. Notably, oral semaglutide tablets should be taken first thing in the morning on an empty stomach with no more than half a glass of plain water (up to 120 mL or 4 fl oz), followed by 30 min before eating food, drinking additional fluids, or ingesting other oral medications. Person-centered clinical discussions between healthcare professionals (HCPs) and patients prior to treatment initiation are important to ensure patients understand administration requirements and why they are necessary, establish realistic expectations for obesity treatment targets, and cover approaches to maintain adherence. HCP-patient consultations should also include discussion of strategies to help patients minimize, prepare for, and manage adverse events. In this article, we provide practical guidance for incorporating oral semaglutide into obesity management, drawing on evidence from clinical trials, including the OASIS 4 trial, and the authors' clinical insights.

项与司美格鲁肽（中山万汉）相关的新闻（医药）

2026-08-18

·genohopebio.com

Brazil Approves Its First Locally Made Generic Of Semaglutide, The Ozempic Weight-Loss Drug

Aug 18, 2026 Leave a message Brazil has approved its first locally made generic of semaglutide, the molecule behind the blockbuster drugs Ozempic and Wegovy. The health regulator Anvisa cleared the injectable pen for domestic maker EMS. With the decision published in the federal gazette on 13 August 2026. A rival copy from fellow Brazilian lab Germed was waved through in the same stretch. Anvisa registered an EMS pen as a full 'generic', the strictest copycat category in Brazilian law. That label means the product must prove it behaves in the body just like the original brand. At the same time, Germed's version, sold as Semaclique, was approved as a 'similar'. Both are injectable pens, and both are made on Brazilian soil. The registrations run for 24 months before they need renewal. However, neither company has yet named a launch date for the new pens. Semaglutide is a large, fiddly molecule, not a simple chemical pill. For that reason, earlier Brazilian versions were logged as 'new medicines', not as clean generics. This week's decision changes that framing. It is the first time the regulator has stamped the coveted 'generic' badge on the weight-loss compound. The difference is more than paperwork. Because a generic must match the reference drug closely, doctors and pharmacists tend to trust the swap. In late July, Anvisa registered five more semaglutide pens from other firms. Those, however, were classed as new synthetic analogs rather than true generics. So the market has filled up fast in stages. First came EMS's Ozivy in May, then July's five analogs, and now this first formal generic. Each wave has widened the field of competitors. As a result, patients should soon face a genuine choice of brands and prices. None of this could happen while Novo Nordisk held its Brazilian patent. That protection finally lapsed in March 2026 after a long court fight. Brazil's Superior Court of Justice upheld the expiry, closing off further appeals. Once the shield fell, local drugmakers raced to file their versions. The Danish maker had fought hard to stretch its monopoly. Even so, the courts sided with the argument that the patent term had run out. EMS is Brazil's largest pharmaceutical company, and Germed sits within the same corporate group. Both run manufacturing inside the country. That local footprint matters for supply. In short, the pens can be produced at home rather than shipped in from abroad. Domestic output can also blunt shortages and currency swings. Meanwhile, it keeps more of the value chain, and the jobs, inside Brazil. Anvisa's paperwork lists the EMS generic for type 2 diabetes in adults. The same molecule, at higher doses, also powers the weight-loss brand Wegovy. Patients inject the medicine under the skin using a pre-filled pen. Because demand is huge, obesity use has driven much of the frenzy. Semaglutide curbs appetite and steadies blood sugar. For that reason, it has become one of the most sought-after medicines in the country. The gazette notice carried no price and no sale date for either new pen. Companies, therefore, have not yet said what shoppers will pay. Still, there is a useful benchmark. EMS launched its earlier Ozivy pen in June at R$452, or about US$89, well under branded Ozempic. EMS also offered a 90-day starter pack for R$863,23, near US$170. That worked out to roughly R$287, about US$56, a month for early buyers. More approved pens should mean more competition, and competition usually drags prices down. For many Brazilians, that is the whole point. The drugs remain expensive and hard to reach on public budgets. As a result, cheaper local copies could widen access over time. Access has been strikingly uneven so far. Because the pens cost so much, many patients have simply gone without. Doctors have also warned about people buying online without guidance. Therefore, wider legal supply could pull risky habits back into the open. The rush has a darker side, and regulators know it. Because the pens are so coveted, counterfeit versions have already surfaced. Health officials have urged buyers to stick to approved products. In short, a cheap pen from an unknown source is a real gamble. The patent loss does not push Novo Nordisk out of Brazil. The Danish firm has been expanding its own local production of the drug. It still owns the trusted Ozempic and Wegovy brands. Therefore, the fight ahead is about price and loyalty, not just supply. Global demand for these injections has exploded in recent years. Brazil, one of the world's biggest drug markets, is a prize worth defending. Regulators are expected to keep approving weight-loss and diabetes pens through the rest of the year. Oral versions and rival molecules are also in the queue. For now, though, the headline is simple. Brazil finally has a home-grown generic of the medicine millions have been chasing. The next test is whether prices actually fall on the shelf. Until the pens reach pharmacies, the promised savings remain a hope, not a receipt. No. EMS launched Ozivy in May and five more pens arrived in July. This is the first one Anvisa classed as a true generic. A generic must match the original almost exactly and sells without a brand name. A similar is close but keeps its own brand, like Germed's Semaclique. The approval listed no price. For context, EMS's earlier Ozivy pen launched around R$452, roughly US$89, below branded Ozempic. It treats both type 2 diabetes and obesity. Demand has soared, so cheaper local copies are seen as a major access win. GenoHope Biotech Ltd. A leading manufacturer of GLP-1 API Approal by FDA Welcome any Inquiry WhatsApp/Tel:+8613833133635 Email:info@genohopebio.com Send Inquiry

上市批准专利侵权

2026-07-06

·歆医荟代谢

[Mini Review] 口服GLP-1药挺进减重加速期：摆脱多肽物理壁垒，肥胖治疗能否真正“无针化”？

作者导语在传统的生物化学认知中，碳水化合物、脂质和氨基酸等代谢产物一直扮演着默默无闻的“燃料”角色，主要负责为细胞生命活动提供能量和构建大分子的原材料。然而，随着化学生物学与表观遗传学研究的交汇深入，科学家们惊奇地发现，这些代谢产物正在悄然进行着一场惊人的“身份转换”。它们不仅是代谢过程的终点或中间体，更是直接参与调控基因表达的“信号使者”。这一发现彻底颠覆了我们对肥胖、糖尿病等代谢性疾病发病机制的传统认知。在代谢性疾病的演变过程中，细胞内的微环境处于持续的波动之中。这种营养过剩或失衡的状态会导致特定代谢产物水平的急剧变化。这些代谢产物作为底物或辅助因子，能够直接影响表观遗传修饰酶的活性，从而在不改变DNA序列的前提下，动态调整基因的转录活性。这种“代谢-表观遗传”的紧密联锁，不仅解释了环境因素如何迅速在基因层面留下烙印，也为临床上长期未解的某些病理谜题提供了全新的分子机制。更为重要的是，这种表观遗传的改变往往具有持久性，甚至在病理刺激被移除后依然存在，这就是临床上令内分泌医生十分头疼的“代谢记忆”效应。本文将结合近年来的重磅前沿研究，为您系统梳理代谢产物如何通过表观遗传修饰在代谢性疾病中发挥“桥梁”作用，并探讨这一前沿领域对未来临床诊疗路径的深远启示。司美格鲁肽：以促吸收辅料突破多肽口服转运的生理屏障作为GLP-1领域的开拓性产品，司美格鲁肽向口服化迈出的第一步具有里程碑意义。然而，作为一种大分子多肽，司美格鲁肽在胃肠道的口服吸收面临多重天然屏障。胃酸的强酸性降解作用、胃粘膜紧密连接限制以及极其低下的上皮细胞渗透性，导致常规情况下多肽药物的口服绝对生物利用度通常低于1%。为了突破这一瓶颈，口服司美格鲁肽采用了创新的吸收促进剂——N-[8-(2-羟基苯甲酰)氨基]辛酸钠（SNAC）。SNAC可以在胃粘膜局部形成微碱性的保护环境，防止司美格鲁肽被胃蛋白酶降解，并通过瞬时促进胃上皮细胞膜的主动跨膜转运，实现大分子多肽的非共价跨膜吸收。然而，即使有SNAC辅料的辅助，口服司美格鲁肽的吸收率依然非常低下且极易受胃内环境干扰。为了达到与注射制剂相当的减重效能，提高临床给药剂量是最直接的策略。在针对非糖尿病超重或肥胖人群的OASIS 1研究中，研究者评估了每日一次口服司美格鲁肽 50 mg 的疗效。结果表明，在接受68周治疗后，50 mg口服组患者的平均体重降幅高达 15.1%，这与注射用司美格鲁肽 2.4 mg（STEP 1研究中平均减重14.9%）的减重水平相当，打破了大分子多肽不能高效口服减重的传统认知。这一临床证据链不仅证实了高剂量口服司美格鲁肽在“无针化”治疗中的高强度效能，也提示我们在临床决策中，大分子口服技术已经具备了与针剂一较高下的实力。但不可忽视的是，由于多肽吸收的脆弱特征，口服司美格鲁肽仍需每日晨起空腹服用，且仅能用不超过120毫升的温水送服，随后必须禁食禁水、不能口服其他药物至少30分钟。这一苛刻的服药限制在现实世界中对患者的长期依从性提出了极大的挑战。 Orforglipron：小分子结构赋能生物利用度跃升与无限制给药由于肽类口服剂在工艺和服用条件上的天然短板，非肽类、人工合成的小分子GLP-1RA成为了新一代的研发方向。作为非肽小分子领域的领头羊，Orforglipron 是一种具有高口服活性的合成非肽类分子。由于其分子结构并非多肽，Orforglipron不会在胃肠道中被蛋白酶降解，更不需要添加SNAC等特殊的化学辅助吸收剂。其绝对口服生物利用度达到了惊人的约79%，相比肽类的微弱吸收实现了跨越式的质的跃升。由于其稳健的胃肠道吸收谱，Orforglipron最核心的临床优势在于服药不受食物、饮水量或晨起时间的限制。患者在进食前或进食后均可服用，极大地简化了每日用药流程。在发表于《新英格兰医学杂志》的一项地标性2期研究中，Orforglipron在超重或肥胖成人中展现出强劲的、剂量依赖性的体重减轻作用。在接受 36周治疗后，Orforglipron 36 mg和45 mg组患者的平均体重降幅分别达到了 12.4% 和 14.7%，且减重曲线在36周时仍未达到平台期。表1，主要终点与次要终点（疗效估计量，efficacy estimand）图1，每日口服orforglipron与安慰剂相比的体重变化这些数据有力表明，非肽类口服小分子药物不仅在疗效上逼近经典注射用多肽，更在日常用药的便利性上彻底重塑了患者体验。患者无须再为清晨的禁食禁水而烦恼，这种“去限制化”的服药方式有望大幅降低患者的中途脱落率，真正实现了肥胖管理的依从性革命。信号传导偏向性：小分子高效能与低脱敏的分子药理学基础为什么非肽类小分子GLP-1RA在具备高吸收效率的同时，能实现不亚于天然多肽的长期效能？其背后的生物物理学和分子药理学机制非常独特。研究发现，Orforglipron等非肽类小分子在与GLP-1受体（GLP-1R）结合时，表现出与天然GLP-1多肽截然不同的配体-受体相互作用特质。它们并不结合GLP-1R的胞外域，而是深入到受体跨膜区独特的疏水结合口袋中。这种特异性的结合方式，使小分子GLP-1RA在受体激活时表现出强烈的“偏向性信号传导（biased signaling）”特征。经典的多肽激动剂在结合GLP-1R后，在激活主要下游效应物环磷酸腺苷（cAMP）通路的同时，也会强烈招募 β-arrestin 1和2 通路。而β-arrestin的募集在细胞生物学层面上是导致受体发生快速脱敏、胞内内吞（internalization）和降解的核心始动因素，这解释了为什么长时间持续多肽刺激下，受体可能产生敏感性下调。相比之下，Orforglipron等非肽类小分子具有极其强烈的 cAMP通路激活偏好，而几乎不招募β-arrestin通路。这种偏向性激活特征显著限制了GLP-1R的快速脱敏与内吞降解，使得受体在靶器官上表现出更为持久稳定的高水平信号传导。这种分子层面的“低脱敏”特性，从药理学维度为小分子口服药物的临床长期有效性提供了坚实的学术支撑。 Aleniglipron与ACCESS研究：多极化口服管线充实“无针化”版图在口服小分子GLP-1RA的研发竞赛中，除了率先挺进临床深水区的Orforglipron，另一款创新口服非肽小分子激动剂——Aleniglipron 同样展现出不俗的实力。发表于《自然·医学》（Nature Medicine）的 ACCESS 2b 研究，为小分子口服减重的多极化格局增添了最新的重磅循证医学证据。 ACCESS 2b是一项多中心、随机、双盲、安慰剂对照的2b期临床研究，共随机化了230名平均体质指数（BMI）高达 39.5 kg/m² 的重度非糖尿病肥胖患者。在接受Aleniglipron治疗后，患者在多个剂量组均展现出了优异的、呈剂量依赖性的体重减轻，且由于其同样具备良好的非多肽口服特性，患者不必在清晨受到严苛的空腹禁水折磨，大幅简化了超重患者在长期生活方式干预下的给药管理。表2，双盲期开始时参与者的人口统计学特征及基线临床特征图2，体重下降情况 Aleniglipron的成功不仅证实了该药在重度肥胖人群中的卓越效能，更向学术界传递了一个重要信号：口服小分子GLP-1RA已呈现出百花齐放的态势。各研发阵营通过特异性的非肽骨架结构、独特的配体结合偏向性，在绝对效能、心血管代谢生物标志物改善以及不同人群耐受性之间进行差异化的探索，共同加速了整体肥胖治疗进入完全“无针化”时代的进程。拓展阅读：尽管口服GLP-1RA在“无针化”和“高依从性”上展现出绝佳的发展前景，但在临床广泛推广前，如何妥善解决其共有的胃肠道不良反应（GI AE）以及由此带来的患者早期脱落问题，依然是内分泌与代谢界关注的核心挑战。大规模的系统评价和网状荟萃分析（Meta-analysis）表明，不论是高剂量口服肽类司美格鲁肽还是新型小分子Orforglipron，其发生率最高的不良事件依然集中在消化系统，表现为一过性至中度的恶心、呕吐、腹泻和便秘。在针对非糖尿病肥胖或超重人群的系统评估中，GLP-1RA引发的胃肠道不良事件往往在用药的前几周（即剂量滴定阶段）最为高发。由于口服药采用每日一次的频繁给药频率，虽然其血药浓度的峰谷波动通过其缓释或长半衰期机制得以部分平抑，但在初始暴露时，对局部胃粘膜和中枢化学感受器的刺激频率可能高于每周仅注射一次的长效注射制剂。为了有效改善口服治疗中的安全耐受性，临床研究均不约而同地强调了“个体化慢剂量滴定（slow titration）”的重要性。荟萃分析证据显示，若采用长达数周、缓慢逐步增加剂量的方式给药，患者因胃肠道不耐受而导致提早终止治疗的比例会显著下降。此外，对于口服小分子制剂，虽然其不限制饮食，但在用药早期尽量避免摄入高脂、高油及辛辣食物，也能大幅缓解早期的反射性胃排空延迟所致的饱胀感。对这部分药物特异性不良事件的精细化临床管理，将是口服药在现实世界中能否发挥出与临床试验同等理论效能的关键所在。观点评述从机制突破、服药限制的重塑到多极临床证据的交汇，口服GLP-1RA药物正在以前所未有的速度迈进肥胖治疗的加速期。口服高剂量司美格鲁肽（OASIS 1）、Orforglipron以及Aleniglipron（ACCESS 2b）等一系列里程碑式试验的渐次发表，预示着代谢类新药研发正在告别单一的“注射制剂主导”模式，构建起一个涵盖多肽与小分子、长效注射与高便捷口服的多元化减重干预版图。然而，我们必须清醒地认识到，虽然“无针化”在提升患者初始接受度和短期用药便利性方面具备极其独特的竞争优势，但这并不意味着口服药在现阶段可以完全颠覆或取代注射制剂。首先，长期心血管及靶器官获益证据依然是皮下注射多肽药物的天然学术护城河。例如，注射用司美格鲁肽已通过重磅的SELECT研究在循证层面上证实了其能够降低非糖尿病肥胖患者20%的主要心血管不良事件（MACE）风险。目前口服小分子制剂的长期心血管结局试验（CVOT）仍处于开展阶段，能否取得完全一致的、独立于降糖和减重的直接器官保护证据，将决定口服药物在临床高危心血管疾病人群中的最终地位。其次，面对极重度肥胖或合并严重多系统代谢紊乱的患者，单靶点口服小分子所带来的体重控制幅度（11%~15%），相比于多靶点注射制剂（如GLP-1/GIP双靶点替尔泊肽可实现>20%的减重）仍有一定差距。对于未来的临床代谢管理趋势而言，“无针化”口服药的最大启示不在于提供一个一劳永逸的终极替代，而在于丰富并优化了临床分流管理机制。在不远的将来，代谢科医生能够对初治、年轻、工作繁忙或常年差旅的轻中度肥胖患者，优先处方不受服用条件限制的新一代小分子口服药物（如Orforglipron），极大地提高其日常依从性并避免疾病进展；而对重度及极度肥胖、或处于多器官疾病中晚期合并严重并发症的患者，则依然以多靶点、大分子注射用多肽为主要武器，从而在整体医疗体系内实现高度精细化的分层定制管理。 ---------------------------------- ☆本文仅供医疗卫生等专业人士参考参考文献 1.Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. 2.Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-888. 3.Rosenstock J, Lingvay I, Ryan D, et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. Published online June 5, 2026. 4.Sloop KW, Cox AL, Wainscott DB, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024;16(778):eadp5765. 5.Ismaiel A, Scarlata GGM, Boitos I, et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes (Lond). 2025;49(10):1946-1957. 声明：歆医荟代谢所发表内容之知识产权为歆医荟及原作者等相关权利人所有。未经许可，禁止进行转载、摘编、复制、裁切、录制等。经许可授权使用，亦须注明来源。欢迎转发、分享。

临床研究

2026-07-03

·Firstwordpharma

UK regulator expands use of Novo's Wegovy into MASH

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk's Wegovy (semaglutide) for metabolic-associated steatohepatitis (MASH). The decision adds to the already authorised indications of obesity management and cardiovascular risk reduction for the GLP-1 agonist.Friday's marketing approval covers adult MASH patients with moderate-to-advanced liver fibrosis and is conditional, requiring further confirmatory evidence from an ongoing study before full authorisation can be granted. Regulators said they will review new safety and efficacy data at least annually."The available evidence indicates that semaglutide is a safe and effective treatment option for patients with MASH," said Julian Beach, executive director of Healthcare Quality and Access at the MHRA.Wegovy became the first GLP-1 to break into MASH when it was granted US approval last year based on data from the Phase III ESSENCE trial where after 72 weeks, 37% of patients showed improved liver scarring without their steatohepatitis getting worse, compared to 22.5% for placebo. Additionally, 62.9% of patients had resolution of steatohepatitis without any increase in liver scarring, while this was true for only 34.1% in the placebo arm.Wegovy was recently approved for the MASH indication in Japan, and is also authorised in the EU under the brand name Kayshild.In an interview with FirstWord last year, key opinion leader (KOL) Jörn Schattenberg suggested liver specialists were likely to reach for Madrigal Pharmaceuticals' rival THR-β agonist Rezdiffra (resmetirom) more at first, particularly in patients who don't need to lose weight, though Wegovy has an advantage because more people know about it and has the marketing power of a major pharma behind it (see – KOL Views Q&A: Wegovy and Rezdiffra could be friends with mutual benefits in MASH).A recent FirstWord survey of US-based gastroenterologists, endocrinologists and hepatologists suggested that Rezdiffra would probably remain a cornerstone MASH treatment, with Wegovy potentially making a bigger dent of its market share among moderate cases (see – Physician Views In-Depth: Wegovy favoured in moderate MASH cases).For additional analysis of the MASH space, see — Vital Signs: Is Madrigal's MASH magic waning? and KOL Views Q&A: Boehringer's survodutide may find an obesity niche while key MASH data mature.

临床结果上市批准临床3期加速审批

100 项与司美格鲁肽（中山万汉）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A10BJ06	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床1期	中国	中山万汉制药有限公司	2025-02-06
2型糖尿病	临床1期	中国	深圳市健翔生物制药有限公司	2025-02-06
肥胖	临床申请批准	中国	中山万汉制药有限公司	2025-12-26